Sign in

Notes in 19 Antivirals

To Subscribe, use this Key

Status Last Update Fields
Published 07/30/2024 3 oral nucleoside analogs are licensed for the treatment of HSV & VZV{{c1::Acyclovir, Valacyclovir, and Famciclovir}}
Published 07/30/2024 QC. Cold sores and genital lesions1. HSV2. VZV{{c1::A}}
Published 07/30/2024 QC. Chicken pox and herpes zoster1. HSV2. VZV{{c1::B}}
Published 07/30/2024 T or FAntivirals for HSV and VZV can also kill latent virus in cells {{c1::False, only act on active that show symptom}}
Published 07/30/2024 Acyclovir is a competitive inhibitor of viral {{c1::DNA polymerase::protein}}
Published 07/30/2024 Most Antivirals for HSV and VZV can termination chain elongation of nucleic acid because they are analogs that lack {{c1::3’OH group}}
Published 07/30/2024 How come Anti-HSV and VZV like acyclovir only act on infected cells and not host cells?{{c1::Require viral THYMIDINE KINASE for initial phosphorylatio…
Published 07/30/2024 Acyclovir is converted to to monophosphate by {{c2::VIRAL Thymidine Kinase}}, then monophosphate is phosphorylated to diphosphate and triphosphate by …
Published 07/30/2024 Two enzymes/proteins that are mutate or change in activity which renders resistance of HSV and VZV to antivirals like acyclovir{{c1::Thymidine kinaseD…
Published 07/30/2024 Resistance to Acyclovir will also favor cross-resistance to which drugs?{{c1::Valacyclovir, Famiciclovir, Peniciclovir, and Ganciclovir}}
Published 07/30/2024 Main indication of Acyclovir {{c1::Prophylaxis for px undergoing organ transplant}}
Published 07/30/2024 Initial HSV infection dose {{c1::400 mg 3x daily or 200mg 5x daily for 7-10 days}}
Published 07/30/2024 Acyclovir dose to immunocompetent adults with VZV{{c1::20mg/kg 4x daily for 5 days}}
Published 07/30/2024 Anti-herpes agents are used for prophylaxis for the prevention of HSV and VZV infection in patients undergoing {{c1::organ transplant::surgical proced…
Published 07/30/2024 How to prevent renal toxicity secondary to crystalluria for px taking acyclovir?{{c1::Slow IV infusion Hydrated}}
Published 07/30/2024 Adverse effects to acyclovir{{c1::Neurotoxicity Acute Renal failureNauseaDiarrhea}}
Published 07/30/2024 QC. Bioavailability 1. Acyclovir2. Valacyclovir {{c1::B}}
Published 07/30/2024 High limit dose of valacyclovir before causing TTP and HUS {{c1::8g per day}}
Published 07/30/2024 QC. Treatment of VZV associated pain 1. Acyclovir2. Valacyclovir{{c1::B}}
Published 07/30/2024 QC. Treat recurrent genital herpes & VZ infection1. Acyclovir2. Valacyclovir{{c1::B}}
Published 07/30/2024 QC. Chronic suppression of recurrent genital herpes:1. Acyclovir2. Valacyclovir {{c1::B}}
Published 07/30/2024 Initial valacyclovir dose for HSV infection {{c1::1g po 2x/day for 7-10 days}}
Published 07/30/2024 QC. Prodrug1. Famciclovir 2. Penciclovir {{c1::A}}
Published 07/30/2024 T or FAcyclovir, Valacyclovir and Penciclovir induce chain termination of replication HSV and VZV{{c1::False}}
Published 07/30/2024 Why does penciclovir not cause chain termination on replication HSV and VZV?{{c1::Due to the presence of 3-OH group, BUT LOOONGER half life}}
Published 07/30/2024 Famciclovir/Penciclovir inhibitor of viral {{c1::DNA polymerase::protein}}
Published 07/30/2024 QC. Triphosphate affinity for viral DNA polymerase1. Acyclovir2. Penciclovir {{c1::A}}
Published 07/30/2024 QC. Triphosphate intracellular concentration and longer effect1. Acyclovir2. Pencyclovir {{c1::B}}
Published 07/30/2024 Adverse effects associated to famciclovir/penciclovir{{c1::Neurotoxicity RashNephrotoxicity Hallucination}}
Published 07/30/2024 Used for the treatment of herpes labialis{{c1::Famciclovir/Penciclovir}}
Published 07/30/2024 Topical agent that is used for recurrent herpes labialis{{c1::Penciclovir}}
Published 07/30/2024 MOA of Docosanol {{c1::Inhibition of fusion between host cell plasma membrane and the HSV envelope: prevents viral entry and replication in a cel…
Published 07/30/2024 OTC Topical agent for orolabial herpes{{c1::Docosanol}}
Published 07/30/2024 MOA of Trifluridine {{c1::Pyrimidine nucleoside - compete for thymidine triphosphate with DNA pol}}
Published 07/30/2024 Primarily for treating keratoconjunctivitis and recurrent epithelial keratitis due to HSV-1 or HSV-2{{c1::Trifluridine}}
Published 07/30/2024 Adverse effect associated to HSV and VZV agentsAcyclovir: {{c3::Nephrotic crystalluria}}Valacyclovir: {{c2::TTP and HUS ( >8 g/day)}}Famciclovir: {…
Published 07/30/2024 T or FAcyclovir, valacyclovir, and famciclovir can be used to treat CMV infections{{c1::False}}
Published 07/30/2024 T or FAcyclovir, Valcyclovir, and Famciclovir are all oral drugs{{c1::True}}
Published 07/30/2024 T or FAcyclovir, Valcyclovir, and Famciclovir are all primarily renal excreted{{c1::True}}
Published 07/30/2024 Anti-CMV drug/s that is/are only taken orally {{c1::Valganciclovir}}
Published 07/30/2024 Characteristic rash of CMV infection on infants{{c1::Blueberry muffin rash}}
Published 07/30/2024 Ganciclovir are converted to monophosphate by viral kinase encoded by CMV gene called {{c1::UL97}}
Published 07/30/2024 Ganciclovir Triphosphate is a competitive inhibitor of {{c1::Deoxy Guanosine Triphosphate (dGTP)::metabolite)}}
Published 07/30/2024 {{c1::Ganciclovir}} is preferred for CMV as compared to Acyclovir
Published 07/30/2024 Adverse affect asociated with ganciclovir {{c1::Bone marrow suppression Peripheral NeuropathyRenal function}}
Published 07/30/2024 Heme growth factors that combat myelosuppresion caused by ganciclovir {{c1::GCS-F or GM CSF}}
Published 07/30/2024 Indication of Ganciclovir {{c1::CMV retinitsCMV esophagitisOrgan transplant prophylaxis }}
Published 07/30/2024 T or FAcyclovir and Valcyclovir is UNSAFE for use among pregnant px{{c1::False}}
Published 07/30/2024 Oral prodrug that is rapidly converted to ganciclovir{{c1::Valganciclovir}}
Published 07/30/2024 Plays a major role in the treatment and prevention of CMV infections in immunocompromised hosts{{c1::Valganciclovir}}
Published 07/30/2024 Main excretion route of Ganciclovir and Valganciclovir {{c1::Renal}}
Published 07/30/2024 Foscarnet is an inorganic {{c1::pyrophosphate::metabolite}} analog that inhibits HSV DNA pol and HIV RT
Published 07/30/2024 Anti CMV agent wtih electrolyte abnormalities and CNS side effects{{c1::Foscarnet}}
Published 07/30/2024 Electrolyte levels that are affected by foscarnet {{c1::HypocalcemiaHypomagnesemiaHypokalemia}}
Published 07/30/2024 Resistance from foscarnet results to mutation in CMV {{c1::UL57}} gene
Published 07/30/2024 Effective in the treatment of end-organ CMV disease including the ganciclovir-resistant disease and acyclovir-resistant HSV{{c1::Foscarnet}}
Published 07/30/2024 Often used as a second line in treating strains of HSV and CMV that have mutated their viral kinases{{c1::Foscarnet}}
Published 07/30/2024 Cidofovir competitively inhibits the incorporation of {{c1::deoxycytidine triphosphate (dCTP)::metabolite}} into viral DNA
Published 07/30/2024 T or F Since Cidofovir is a nucleoside analog for CMV infection, it required phosphorylation by viral kinase{{c1::False}}
Published 07/30/2024 Two methods to prevent nephrotoxicity with Cidofovir medication {{c1::Hydration Probenecid}}
Published 07/30/2024 T or FIf there is an alteration on the thymidine kinase or UL97 CMV transferase, Cidofovir must not be given {{c1::False}}
Published 07/30/2024 MOA of Letermovir {{c1::AntiCMV - Inhibiting a component of the viral DNA terminase complex required for DNA packaging and processing}}
Published 07/30/2024 Its antiviral activity is highly specific to CMV, and it is currently the most active molecule against CMV{{c1::Letermovir}}
Published 07/30/2024 ROA of Letermovir {{c1::Oral and IV}}
Published 07/30/2024 MOA of Maribavir {{c1::Anti-CMV - Acts as UL97 inhibitor and blocking the egress of viral capsids}}
Published 07/30/2024 Novel CMV agents: MOAMaribavir: {{c3::UL97 inhibition}}Brincidofovir: {{c2::UL54 inhibition }}Letermovir: {{c1::UL56 inhibtion}}
Published 07/30/2024 CMV agent that can be used for HIV 1 and 2 {{c1::Foscarnet}}
Published 07/30/2024 CMV agent that can be used for Adenovirus and Poxvirus{{c1::Cidofovir}}
Published 07/30/2024 Which among the HSV, VZV, and CMV agents DOES NOT need viral kinase for activation {{c1::Foscarnet and Cidofovir}}
Published 07/30/2024 T or FUnlike HSV/VZV agents, all CMV agents result to chain termination {{c1::True}}
Published 07/30/2024 Influenza {{c1::A::class}} viruses are known to cause the flu pandemic
Published 07/30/2024 Influenza viruses subtypes based on surface proteins {{c1::Hemagglutinin (H)Neuraminidase (N)}}
Published 07/30/2024 Enumeration of Influenza AgentsEndonuclease inhibitor{{c3::Baloxavir Marboxil::1}}Neuraminidase inhibitor (N){{c2::Oseltamivir (oral)Zanamivir (inhale…
Published 07/30/2024 CBA. Influenza agent acitvity AdamantanesA. Influenza AB. Influenza BC. Influenza C{{c1::A}}
Published 07/30/2024 CBA. Influenza agent acitvity Neuraminidase inhibitorsA. Influenza AB. Influenza BC. Influenza C{{c1::A and B}}
Published 07/30/2024 CBA. Influenza agent acitvity Endonuclease inhibitorA. Influenza AB. Influenza BC. Influenza C{{c1::A and B}}
Published 07/30/2024 Influenza agent drug that usually pair with Bolaxavir for synergistic activity {{c1::Oseltamivir::N inhibitor}}
Published 07/30/2024 Cap-dependent endonuclease inhibitor that interferes with viral RNA transcription and blocks virus replication{{c1::Baloxavir Marboxil}}
Published 07/30/2024 Dosage for Baloxavir {{c1::40 mg dose - 40 kg - < 80 kg}}
Published 07/30/2024 Most Influenza agent drugs must be given within {{c1::48}} hours of onset of symptoms 
Published 07/30/2024 Potential for synergism between oseltamivir with {{c1::baloxavir}}
Published 07/30/2024 Primary excretion route of Baloxavir {{c1::Feces}}
Published 07/30/2024 T or FBaloxavir can be given to Pregnant px {{c1::False}}
Published 07/30/2024 Indicated use of Baloxavir {{c1::Flu viruses that are resistant to oseltamivir 5-12 years old (no chronic conditions)}}
Published 07/30/2024 Neuraminidase class dosage{{c1::75 mg BID for 5 days , WITHIN 48 hrs of symptom onset}}
Published 07/30/2024 MOA of Neuraminidase inhibitors {{c1::They interfere with release of progeny Influenza A and B virus from infected host cells}}
Published 07/30/2024 Early administration is crucial because replication of influenza virus peaks at {{c1::24-72}} hours after the onset of illness
Published 07/30/2024 Indication for neuraminidase inhibitor {{c1::Acute uncomplicated influenza}}
Published 07/30/2024 CBA. Neuraminidase inhibitor Oral ROAA. Oseltamivir B. Zanamivir C. Peramivir {{c1::A}}
Published 07/30/2024 CBA. Neuraminidase inhibitor Inhalation ROAA. Oseltamivir B. Zanamivir C. Peramivir {{c1::B}}
Published 07/30/2024 CBA. Neuraminidase inhibitor IV ROAA. Oseltamivir B. Zanamivir C. Peramivir {{c1::C}}
Published 07/30/2024 CBA. Neuraminidase inhibitor Indicated for Children and adultsA. Oseltamivir B. Zanamivir C. Peramivir {{c1::A and C}}
Published 07/30/2024 CBA. Neuraminidase inhibitor Indicated for 7 years old and olderA. Oseltamivir B. Zanamivir C. Peramivir {{c1::B}}
Published 07/30/2024 CBA. Neuraminidase inhibitor Diarrhea, Hypersensitivity reaction Side effectA. Oseltamivir B. Zanamivir C. Peramivir {{c1::C}}
Published 07/30/2024 Stage of viral life cycle that is acted on by Adamantanes{{c1::Viral uncoating}}
Published 07/30/2024 QC. Influenza A activity 1. Amantadine2. Rimantadine{{c1::C}}
Published 07/30/2024 QC. Renal elimination 1. Amantadine2. Rimantadin{{c1::A}}
Published 07/30/2024 QC. Metabolized in the liver1. Amantadine2. Rimantadine{{c1::B}}
Published 07/30/2024 QC. GI upsets and CNS manifestations1. Amantadine2. Rimantadine{{c1::C}}
Published 07/30/2024 QC. Anticholinergic effects1. Amantadine2. Rimantadine{{c1::A}}
Published 07/30/2024 CBA. HepatitisAcquired through intake of contaminated foodA. HAVB. HBVC. HCV{{c1::A}}
Published 07/30/2024 CBA. HepatitisAcquired from infected blood and other body fluidsA. HAVB. HBVC. HCV{{c1::B and C}}
Published 07/30/2024 CBA. HepatitisChronic form infectionA. HAVB. HBVC. HCV{{c1::B and C}}
Published 07/30/2024 T or FUtilization of vaccine for HBV and HCV is the best method of prevention {{c1::False - no vaccine for HCV yet}}
Published 07/30/2024 Two class of HBV agents {{c1::Nucleoside/Nucleotide agentsInterferons}}
Published 07/30/2024 HBV agents that can be used for Retrovirals{{c1::Lamivudine Tenofovir}}
Published 07/30/2024 Enumerate HBV agents under nucleoside analog class{{c1::Lamivudine Adefovir dipivoxil Tenofovir disoproxil/Tenofovir AlafenamideEntecavirTel…
Published 07/30/2024 Lamivudine inhibit HIV {{c2::reverse transcriptase::protein}} and HBV {{c1::DNA pol::protein}}
Published 07/30/2024 Dosage for Lamivudine HBV{{c1::100 mg daily}}
Published 07/30/2024 Dosage for Lamivudine HIV{{c1::300 mg daily}}
Published 07/30/2024 QC. Lamivudin efficacy 1. HBV infection 2. HIV infection {{c1::A}}
Published 07/30/2024 Nucleoside analog that can be used to reduce risk of child infection with hepatitis virus {{c1::Lamivudine}}
Published 07/30/2024 Dosage of Adefovir Dipivoxil for HBV {{c1::10 mg daily orally}}
Published 07/30/2024 T or FNo resistance to tenofovir has not been documented in clinical trials{{c1::True}}
Published 07/30/2024 Dosage of TDF for HBV {{c1::300 mg daily }}
Published 07/30/2024 Dosage of TAF for HBV {{c1::25 mg daily}}
Published 07/30/2024 Only approved nucleotide analog with efficacy to HBV but no detectable clinical resistance to date{{c1::Tenofovir}}
Published 07/30/2024 {{c1::Tenofovir disoproxil fumarate (TDF)::HBV drug}} for pregnant patients with chronic hepatitis B (CHB)
Published 07/30/2024 QC. Effective even at lower doses1. TAF2. TDF{{c1::A}}
Published 07/30/2024 TDF side effects{{c1::Nephrotoxicity Osteoporosis}}
Published 07/30/2024 QC. Lesser intensity of side effects1. TAF2. TDF{{c1::A}}
Published 07/30/2024 First line agents for treatment of chronic hepatitis B{{c1::Entecavir Tenofovir alafenamideTenofovir disoproxil fumarate}}
Published 07/30/2024 QC. Thymidine nucleoside analog1. Entecavir 2. Telbivudine {{c1::B}}
Published 07/30/2024 QC. Guanosine nucleoside analog1. Entecavir 2. Telbivudine {{c1::A}}
Published 07/30/2024 Weak anti-HIV activity and can induce development of the M184V variant{{c1::Entecavir}}
Published 07/30/2024 Entecavir Side Effect{{c1::Lactic acidosis HeadacheFatigue Nausea}}
Published 07/30/2024 Entecavir MOA {{c1::Inhibition of base priming Inhibition of  RT of negative strand Inhibition of Synthesis of positive stran…
Published 07/30/2024 IFN-alpha induces {{c1::Apobec3G}} protein expression as protective factor for those without HBV infection
Published 07/30/2024 Side effects of IFN-alpha against HBV {{c1::Flu-like symptomsNeurotoxicity}}
Published 07/30/2024 QC. Treatment of chronic HBV and HCV1. Peg IFN alpha-2a2. Peg IFN alpha-2B{{c1::A}}
Published 07/30/2024 QC. Peg IFN alpha1. Chronic HBV2. Chronic HCV{{c1::C}}
Published 07/30/2024 Primary efficacy endpoint of HCV treatment would be achievement of {{c1::sustained viral response (SVR)}} or the absence of detectable viremia {{c2::2…
Published 07/30/2024 Thre main classess of direct acting HCV drugs{{c1::NS5A inhibitors (-Asvir)NS5B inhibitors (-Buvir)NS3/4A Protease inhibitors (-Previr)}}
Published 07/30/2024 Enumerate NS5A inhibitors {{c1::Ledipasvir, Ombitasvir, Velpatasvir, Elbasvir, Pibrentasvir, Daclatasvir}}
Published 07/30/2024 Enumerate NS5B inhibitors{{c1::Dasabuvir, Sofosbuvir}}
Published 07/30/2024 Enumerate NS3/4A Protease inhibitors{{c1::Glecaprevir, Grazoprevir, Simeprevir, Paritaprevir, Voxiprevir}}
Published 07/30/2024 CBA. Mechanism of action Inhibit virion asembly and releaseA. NS5a inhibitor B. NS5b inhibitor C. NS3/4a inhibitor{{c1::A}}
Published 07/30/2024 CBA. Mechanism of action Inhibit translation and polyprotein processingA. NS5a inhibitor B. NS5b inhibitor C. NS3/4a inhibitor{{c1::C}}
Published 07/30/2024 CBA. Mechanism of action Inhibit RNA processingA. NS5a inhibitor B. NS5b inhibitor C. NS3/4a inhibitor{{c1::b}}
Published 07/30/2024 QC. Nucleoside/ nucleotide analogs1. Sofosbuvir2. Dasabuvir {{c1::A}}
Published 07/30/2024 Prodrug that after ingestion it is converted into GS-331007{{c1::Sofosbuvir}}
Published 07/30/2024 Offers a potent treatment for hepatitis C{{c1::Glecaprevir}}
Published 07/30/2024 NS3/4A inhibitor with photosensitvity side effect{{c1::Simeprevir}}
Published 07/30/2024 First pangenotypic fixed dose table that includes medication from different antiviral class{{c1::Voxilaprevir}}
Published 07/30/2024 HIV infects a variety of cells of the immune system, including{{c1::CD4 Helper T cellsMacrophagesDendritic cells}}
Published 07/30/2024 CBA. HIV genesMakes the structural proteins (matrix and capsid)A. envB. gagC. pol {{c1::B}}
Published 07/30/2024 CBA. HIV genesMakes the enzymes that are essential for making new virusesA. envB. gagC. pol {{c1::C}}
Published 07/30/2024 QC. Docking of HIV 1. Gp1202. Gp41{{c1::A}}
Published 07/30/2024 QC. Fusion of HIV1. Gp1202. Gp41{{c1::B}}
Published 07/30/2024 QC. Bind to RT enzyme directly 1. NRTI2. NNRTI {{c1::B}}
Published 07/30/2024 6 major classes of ARTs{{c1::NRTIs (Nucleoside / nucleotide reverse transcriptase inhibitors)NNRTIs (non nucleoside reverse transcriptase inhibitors)P…
Published 07/30/2024 Administration of combination ARTs that include at least {{c1::3}} antiretroviral agents (ARVs) with different susceptibility patterns
Published 07/30/2024 Weeks delay before ART medication in ff. comorbiditiesTB infecton: {{c2::2 weeks}}Cryptococcoal infection: {{c1::5 - 6 weeks}}CMV retinitis:…
Published 07/30/2024 VR1. Gastric acidity 2. Absorption of antiretrovirals {{c1::A}}
Published 07/30/2024 Pharmacokinetic enhancers (Boosters) of Antiretrovirals {{c1::RitonavirCobicistat}}
Published 07/30/2024 MOA of Ibalizumab {{c1::HIV entry inhibitor - Monoclonal antibody that binds the CD4 receptor}}
Published 07/30/2024 Only approved CCR5 antagonist (binds only to CCR5){{c1::Maraviroc}}
Published 07/30/2024 Contraindication of Maraviroc {{c1::End stage renal impairment}}
Published 07/30/2024 MOA of Enfuvirtide{{c1::Bind to the envelope glycoprotein 41 (gp41) of HIV to prevent viral fusion to the CD4 T cell}}
Published 07/30/2024 Enumerate NRTI agents{{c1::Lamivudine, Abacavir, Tenofovir disoproxil fumarate, Tenofovir alafenamide, Emtricitabine}}
Published 07/30/2024 Patients who carry the HLAB*5701 allele are at higher risk of hypersensitivity reaction from this Antiretroviral agent {{c1::Abacavir}}
Published 07/30/2024 Abacavir dosage for HIV{{c1::600 mg once a day}}
Published 07/30/2024 {{c1::Emicitrabine}} and {{c2::lamivudine}} may select for the M184V/I mutation and therefore should not be used together
Published 07/30/2024 Emtricitabine side affect{{c1::Hyperpigmentation of the palms or soles may be observed}}
Published 07/30/2024 Active form of Tenofovir {{c1::Tenofovir diphosphate}}
Published 07/30/2024 Immediate discontinuation of this antiviral drug can exacerbate HBV infection {{c1::Tenofovir}}
Published 07/30/2024 Adverse effects associated with Tenofovir {{c1::Fanconi syndrom Acute kidney injury Bone lossSteatosis Lactic acidosis}}
Published 07/30/2024 {{c1::Creatinine}} levels should be monitored with Tenofovir medication
Published 07/30/2024 QC. Associated with greater weight gain and increased LDL1. TDF2. TAF{{c1::B}}
Published 07/30/2024 NRTI that is recommended for pregnant px{{c1::AbacavirEmtricitabine Lamivudin Tenofovir}}
Published 07/30/2024 Most commonly used NNRTI for patients with drug-resistant virus{{c1::Etravirine}}
Published 07/30/2024 NNRTI with multiple drug interactions{{c1::Etravirine}}
Published 07/30/2024 NNRTI associated with SJS and increased toxicity especially during the first 3 months of therapy{{c1::Nevirapine}}
Published 07/30/2024 Alternate NNRTI drug for pregnant px {{c1::EfavirenzRilpivirine}}
Published 07/30/2024 NNRTi associated with eosinophilia and hepatoxicity {{c1::Rilpivirine}}
Published 07/30/2024 NNRTI associated with CNS manifestation and psychiatric symptoms{{c1::Efavirenz}}
Published 07/30/2024 INSTIs that have high genetic barrier to resistance {{c1::BictegravirDolutegravir}}
Published 07/30/2024 INSTI associated with Neural tube defects{{c1::Dolutegravir}}
Published 07/30/2024 INSTI recommended for pregnant px{{c1::DolutegravirRaltegravir}}
Published 07/30/2024 Long acting injectable integrase inhibitor, given IM once a month {{c1::Cabotegravir}}
Published 07/30/2024 Protease inhibitors competitively inhibits the cleavage of the {{c1::Gag-Pol}} polyproteins in HIV-infected cells
Published 07/30/2024 QC. High barrier of resistance1. Protease inhibitors2. NNRTI{{c1::A}}
Published 07/30/2024 Enumerate viable Protease inhibitors {{c1::LopinavirAtazanvirRitonavirDarunavir}}
Published 07/30/2024 CBA. Other antiviral agentsUsed for treatment for condyloma acuminateA. InterferonB. Ribavirin C. PalivizumabD. Imiquimod {{c1::A}}
Published 07/30/2024 CBA. Other antiviral agentsRespiratory Syncytial Virus (RSV), bronchiolitis or pneumonia to reduce the severityA. InterferonB. Ribavirin C. Paliv…
Published 07/30/2024 CBA. Other antiviral agentsHumanized monoclonal antibody directed against RSV in high-risk infantsA. InterferonB. Ribavirin C. PalivizumabD. Imiq…
Published 07/30/2024 CBA. Other antiviral agentsTopical treatment of external genital and perianal warts; immune response modifierA. InterferonB. Ribavirin C. Paliviz…
Published 07/30/2024 Preferred regiment for nonpregnant treatment of naive adults with HIV {{c1::2 NRTI and 1 INSTI}}
Published 07/30/2024 Two specific regimens included for initiation of ART with nonpregnant patients{{c1::Bictegravir-emtricitabine-tenofovir alafenamideDolutegravir plus t…
Status Last Update Fields

Terms of Service | Privacy Policy | Imprint (German)

Copyright © AnkiCollab. Website Template Designed & Developed by Quixlab 2018